| Publication |
Sentence |
Publish Date |
Extraction Date |
Species |
| L Park, J T Nigg, I D Waldman, K A Nummy, C Huang-Pollock, M Rappley, K H Frideric. Association and linkage of alpha-2A adrenergic receptor gene polymorphisms with childhood ADHD. Molecular psychiatry. vol 10. issue 6. 2005-07-27. PMID:15520832. |
although the noradrenergic (na) system is thought to mediate a portion of the pathophysiology of adhd, genes in this pathway have not been investigated as frequently as those in the dopaminergic system. |
2005-07-27 |
2023-08-12 |
Not clear |
| Bowen Chung, Alejandra R Suzuki, James J McGoug. New drugs for treatment of attention-deficit/hyperactivity disorder. Expert opinion on emerging drugs. vol 7. issue 2. 2005-07-13. PMID:15989550. |
the underlying pathophysiology of adhd has been theorised to be dysregulation of inhibitory noradrenergic frontocortical activity on dopaminergic striatal structures. |
2005-07-13 |
2023-08-12 |
Not clear |
| Robert D Oades, Adolfo G Sadile, Terje Sagvolden, Davide Viggiano, Alessandro Zuddas, Paola Devoto, Heidi Aase, Espen B Johansen, Lucia A Ruocco, Vivienne A Russel. The control of responsiveness in ADHD by catecholamines: evidence for dopaminergic, noradrenergic and interactive roles. Developmental science. vol 8. issue 2. 2005-06-17. PMID:15720370. |
the control of responsiveness in adhd by catecholamines: evidence for dopaminergic, noradrenergic and interactive roles. |
2005-06-17 |
2023-08-12 |
human |
| Aaron J Bobb, Anjene M Addington, Ellen Sidransky, Michele C Gornick, Jason P Lerch, Deanna K Greenstein, Liv S Clasen, Wendy S Sharp, Gale Inoff-Germain, Fabienne Wavrant-De Vrièze, Mauricio Arcos-Burgos, Richard E Straub, John A Hardy, F Xavier Castellanos, Judith L Rapopor. Support for association between ADHD and two candidate genes: NET1 and DRD1. American journal of medical genetics. Part B, Neuropsychiatric genetics : the official publication of the International Society of Psychiatric Genetics. vol 134B. issue 1. 2005-05-09. PMID:15717291. |
net1 is implicated in adhd because of the efficacy of atomoxetine, a selective noradrenergic reuptake inhibitor, in the treatment of adhd. |
2005-05-09 |
2023-08-12 |
mouse |
| Katharina Domschke, Karen Sheehan, Naomi Lowe, Aiveen Kirley, Celine Mullins, Roderick O'sullivan, Christine Freitag, Tim Becker, Judith Conroy, Michael Fitzgerald, Michael Gill, Ziarih Haw. Association analysis of the monoamine oxidase A and B genes with attention deficit hyperactivity disorder (ADHD) in an Irish sample: preferential transmission of the MAO-A 941G allele to affected children. American journal of medical genetics. Part B, Neuropsychiatric genetics : the official publication of the International Society of Psychiatric Genetics. vol 134B. issue 1. 2005-05-09. PMID:15717295. |
pharmacological and genetic studies suggest the importance of the dopaminergic, serotonergic, and noradrenergic systems in the pathogenesis of attention deficit hyperactivity disorder (adhd). |
2005-05-09 |
2023-08-12 |
Not clear |
| Vincenzo De Luca, Pierandrea Muglia, John B Vincent, Matthew Lanktree, Umesh Jain, James L Kenned. Adrenergic alpha 2C receptor genomic organization: association study in adult ADHD. American journal of medical genetics. Part B, Neuropsychiatric genetics : the official publication of the International Society of Psychiatric Genetics. vol 127B. issue 1. 2004-11-02. PMID:15108182. |
pharmacological interventions, such as the new selective noradrenergic reuptake inhibitor, atomoxetine, suggest the adrenergic system as candidate in adhd. |
2004-11-02 |
2023-08-12 |
Not clear |
| Virginia L Misener, Russell Schachar, Abel Ickowicz, Molly Malone, Wendy Roberts, Rosemary Tannock, James L Kennedy, Tejaswee Pathare, Cathy L Bar. Replication test for association of the IL-1 receptor antagonist gene, IL1RN, with attention-deficit/hyperactivity disorder. Neuropsychobiology. vol 50. issue 3. 2004-10-19. PMID:15365221. |
attention-deficit/hyperactivity disorder (adhd) has a strong genetic basis, and aberrant brain dopaminergic and noradrenergic activity is implicated in its etiology. |
2004-10-19 |
2023-08-12 |
Not clear |
| Vincenzo De Luca, Pierandrea Muglia, Umesh Jain, James L Kenned. No evidence of linkage or association between the norepinephrine transporter (NET) gene MnlI polymorphism and adult ADHD. American journal of medical genetics. Part B, Neuropsychiatric genetics : the official publication of the International Society of Psychiatric Genetics. vol 124B. issue 1. 2004-07-28. PMID:14681910. |
the mechanism of action of the new selective noradrenergic reuptake inhibitor, atomoxetine, efficacious in the treatment of adhd symptoms, suggests that the norepinephrine transporter (net) may be involved in adhd. |
2004-07-28 |
2023-08-12 |
Not clear |
| Tatiana Roman, Luis Augusto Rohde, Mara Helena Hut. Polymorphisms of the dopamine transporter gene: influence on response to methylphenidate in attention deficit-hyperactivity disorder. American journal of pharmacogenomics : genomics-related research in drug development and clinical practice. vol 4. issue 2. 2004-07-26. PMID:15059031. |
although the neurobiology of adhd is not completely understood, imbalances in both dopaminergic and noradrenergic systems have been implicated in the origin and persistence of core symptoms, which include inattention, hyperactivity, and impulsivity. |
2004-07-26 |
2023-08-12 |
Not clear |
| Tatiana Roman, Marcelo Schmitz, Guilherme V Polanczyk, Mariana Eizirik, Luis A Rohde, Mara H Hut. Is the alpha-2A adrenergic receptor gene (ADRA2A) associated with attention-deficit/hyperactivity disorder? American journal of medical genetics. Part B, Neuropsychiatric genetics : the official publication of the International Society of Psychiatric Genetics. vol 120B. issue 1. 2004-02-19. PMID:12815749. |
they are also consistent with the noradrenergic theories of adhd, suggesting a role for the alpha2a adrenergic receptors in the disorder. |
2004-02-19 |
2023-08-12 |
Not clear |
| Michelle D Jones, Ellen J Hes. Norepinephrine regulates locomotor hyperactivity in the mouse mutant coloboma. Pharmacology, biochemistry, and behavior. vol 75. issue 1. 2004-01-07. PMID:12759129. |
an imbalance between dopaminergic and noradrenergic systems is implicated in hyperactivity disorders such as attention deficit hyperactivity disorder (adhd) and tourette syndrome. |
2004-01-07 |
2023-08-12 |
mouse |
| Jeffrey M Halperin, Jeffrey H Newcorn, Kathleen E McKay, Larry J Siever, Vanshdeep Sharm. Growth hormone response to guanfacine in boys with attention deficit hyperactivity disorder: a preliminary study. Journal of child and adolescent psychopharmacology. vol 13. issue 3. 2003-12-19. PMID:14642016. |
this preliminary study evaluated a method for assessing central noradrenergic function in children via the growth hormone response to a single dose of the alpha-2 adrenergic receptor agonist guanfacine and examined whether this measure distinguishes between attention deficit hyperactivity disorder (adhd) boys with and without reading disabilities (rd). |
2003-12-19 |
2023-08-12 |
Not clear |
| C C E Overtoom, M N Verbaten, C Kemner, J L Kenemans, H van Engeland, J K Buitelaar, M W van der Molen, J van der Gugten, H Westenberg, R A A Maes, H S Koeleg. Effects of methylphenidate, desipramine, and L-dopa on attention and inhibition in children with Attention Deficit Hyperactivity Disorder. Behavioural brain research. vol 145. issue 1-2. 2003-12-10. PMID:14529800. |
the objective of this study was to investigate the effects of methylphenidate (mph) on attention and inhibition in children with attention deficit hyperactivity disorder (adhd) and to establish what the relative contributions of the noradrenergic and dopaminergic systems to this effect were. |
2003-12-10 |
2023-08-12 |
Not clear |
| J Biederman, S V Faraon. Current concepts on the neurobiology of Attention-Deficit/Hyperactivity Disorder. Journal of attention disorders. vol 6 Suppl 1. 2003-05-22. PMID:12685515. |
although not entirely sufficient, changes in dopaminergic and noradrenergic function appear necessary for the clinical efficacy of pharmacological treatments for adhd, providing support for the hypothesis that alteration of monoaminergic transmission in critical brain regions may be the basis for therapeutic action in adhd. |
2003-05-22 |
2023-08-12 |
Not clear |
| Bennett L Lavenstei. Treatment approaches for children with Tourette's syndrome. Current neurology and neuroscience reports. vol 3. issue 2. 2003-04-28. PMID:12583843. |
drug treatment has included dopamine receptor blockers for tics, dopamine agonists, dopamine depletors, and stimulants for attention deficit hyperactivity disorder (adhd), noradrenergic drugs for tics and adhd, serotonergic drugs for ocd, and chemical denervation for involuntary movements with the use of botulinum toxin and stereotactic surgery. |
2003-04-28 |
2023-08-12 |
Not clear |
| Lenard A Adler, Hong C Chu. Management of ADHD in adults. The Journal of clinical psychiatry. vol 63 Suppl 12. 2003-02-11. PMID:12562059. |
molecular genetics and neuroimaging studies confirm that adhd is a heterogeneous, neurobiological disorder, mainly of dopaminergic and noradrenergic pathways. |
2003-02-11 |
2023-08-12 |
Not clear |
| Thomas Spencer, Joseph Biederman, Barbara Coffey, Daniel Geller, Margaret Crawford, Sarah Kate Bearman, Reem Tarazi, Stephen V Faraon. A double-blind comparison of desipramine and placebo in children and adolescents with chronic tic disorder and comorbid attention-deficit/hyperactivity disorder. Archives of general psychiatry. vol 59. issue 7. 2002-08-06. PMID:12090818. |
to address this issue, we evaluated the tolerability and efficacy of the noradrenergic tricyclic antidepressant desipramine hydrochloride in the treatment of children and adolescents with chronic tic disorders and comorbid adhd. |
2002-08-06 |
2023-08-12 |
Not clear |
| Karen Wigg, Gwyneth Zai, Russell Schachar, Rosemary Tannock, Wendy Roberts, Molly Malone, James L Kennedy, Cathy L Bar. Attention deficit hyperactivity disorder and the gene for dopamine Beta-hydroxylase. The American journal of psychiatry. vol 159. issue 6. 2002-06-21. PMID:12042196. |
attention deficit hyperactivity disorder (adhd) has been shown to be highly heritable, and recent molecular genetics studies have focused on candidate genes in the dopaminergic and noradrenergic systems. |
2002-06-21 |
2023-08-12 |
Not clear |
| Cathy L Barr, Jamie Kroft, Yu Feng, Karen Wigg, Wendy Roberts, Molly Malone, Abel Ickowicz, Russell Schachar, Rosemary Tannock, James L Kenned. The norepinephrine transporter gene and attention-deficit hyperactivity disorder. American journal of medical genetics. vol 114. issue 3. 2002-06-17. PMID:11920844. |
the efficacy of the highly selective noradrenergic reuptake inhibitor, tomoxetine, in treating adhd symptoms supports the system's role in adhd and points to the norephinephrine transporter as a candidate gene. |
2002-06-17 |
2023-08-12 |
Not clear |
| Vivienne Ann Russel. Hypodopaminergic and hypernoradrenergic activity in prefrontal cortex slices of an animal model for attention-deficit hyperactivity disorder--the spontaneously hypertensive rat. Behavioural brain research. vol 130. issue 1-2. 2002-05-16. PMID:11864734. |
evidence supports dysfunction of dopaminergic and noradrenergic systems in patients with attention-deficit hyperactivity disorder (adhd). |
2002-05-16 |
2023-08-12 |
rat |